The Role of Lapatinib in the Preoperative Therapy of Breast Cancer

被引:0
作者
Hirsh, Rebecca L. [1 ,2 ]
DeMichele, Angela [1 ,2 ,3 ]
机构
[1] Univ Penn, Dept Med, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
Neoadjuvant; HER2; Lapatinib; Trastuzumab; Breast cancer; PATHOLOGICAL COMPLETE RESPONSE; PHASE-II TRIAL; NEOADJUVANT THERAPY; ADJUVANT CHEMOTHERAPY; STAGE-II; TRASTUZUMAB; PLUS; DOCETAXEL; PACLITAXEL;
D O I
10.1007/s11912-011-0206-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Preoperative or neoadjuvant chemotherapy is a well-established modality in the treatment of nonmetastatic breast cancer. Patients initially considered inoperable may be able to achieve operable status after preoperative chemotherapy and patients initially considered not to be candidates for breast conservation may convert to breast conservation status. Human epidermal growth factor receptor 2 (Her2)-positive tumors have been shown to have a more aggressive course including early local relapse and metastasis when compared to Her2-negative breast cancers, but the optimal use of Her2-targeted agents is constantly evolving as new agents become available. Preoperative studies allow us to quickly assess the activity of new agents and combinations for particular biological subsets of breast cancer.
引用
收藏
页码:44 / 47
页数:4
相关论文
共 50 条
  • [41] Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Ye Yuan
    Xumei Liu
    Yi Cai
    Wenyuan Li
    Systematic Reviews, 11
  • [42] Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience
    Crivellari, Diana
    Spazzapan, Simon
    Lombardi, Davide
    Militello, Loredana
    Torrisi, Elena
    Russo, Alessia E.
    Sorio, Roberto
    Talamini, Renato
    Miolo, Gianmaria
    Carli, Paolo
    Veronesi, Andrea
    TUMORI JOURNAL, 2012, 98 (01): : 33 - 38
  • [43] Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment
    Zhou, Xiaolei
    Cella, David
    Cameron, David
    Amonkar, Mayur M.
    Segreti, Anthony
    Stein, Steven
    Walker, Mel
    Geyer, Charles E.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (03) : 577 - 589
  • [44] A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer
    Jagiello-Gruszfeld, Agnieszka
    Tjulandin, Sergei
    Dobrovolskaya, Natalya
    Manikhas, Alexey
    Pienkowski, Tadeusz
    DeSilvio, Michelle
    Ridderheim, Mona
    Abbey, Rowena
    ONCOLOGY, 2010, 79 (1-2) : 129 - 135
  • [45] Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study
    Catharina Wenzel
    Dagmar Hussian
    Rupert Bartsch
    Ursula Pluschnig
    Gottfried J. Locker
    Margarethe Rudas
    Michael F. Gnant
    Raimund Jakesz
    Christoph C. Zielinski
    Guenther G. Steger
    Journal of Cancer Research and Clinical Oncology, 2004, 130 : 400 - 404
  • [46] Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study
    Wenzel, C
    Hussian, D
    Bartsch, R
    Pluschnig, U
    Locker, GJ
    Rudas, M
    Gnant, MF
    Jakesz, R
    Zielinski, CC
    Steger, GG
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (07) : 400 - 404
  • [47] Combination Therapy of Lapatinib and Capecitabine for ErbB2-Positive Metastatic or Locally Advanced Breast Cancer: Results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe
    Greil, Richard
    Borstnar, Simona
    Petrakova, Katarina
    Marcou, Yiola
    Pikiel, Joanna
    Wojtukiewicz, Marek Z.
    Koza, Ivan
    Steger, Guenther G.
    Linn, Meinolf
    Das Gupta, Ash
    Cwiertka, Karel
    ONKOLOGIE, 2011, 34 (05): : 233 - 238
  • [48] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06) : 661 - 666
  • [49] Target therapy in elderly breast cancer patients
    Carli, Paolo
    Turchet, Elisa
    Quitadamo, Daniela
    Spada, Antonella
    Miolo, Gianmaria
    Lamaj, Elda
    Spazzapan, Simon
    Di Lauro, Vincenzo
    Dolcetti, Riccardo
    Veronesi, Andrea
    Crivellari, Diana
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 83 (03) : 422 - 431
  • [50] Cardiomyopathy Associated With Targeted Therapy for Breast Cancer
    Sivagnanam, Kamesh
    Rahman, Zia U.
    Paul, Timir
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2016, 351 (02) : 194 - 199